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ABSTRACT: Oral administration of a solid dosage form
requires drug dissolution in the gastrointestinal tract before
absorption. Solubility is a key factor controlling dissolution,
and it is recognized that, within the intestinal tract, this is
inﬂuenced by the luminal ﬂuid pH, amphiphile content, and
composition. Various simulated intestinal ﬂuid recipes have
been introduced to mimic this behavior and studied using a
range of diﬀerent experimental techniques. In this article, we
have measured equilibrium solubility utilizing a novel four
component mixture design (4CMD) with biorelevant
amphiphiles (bile salt, phospholipid, oleate, and monoglycer-
ide) within a matrix of three pH values (5, 6, and 7) and total
amphiphile concentrations (11.7, 30.6, and 77.5 mM) to
provide a topographical and statistical overview. Three poorly soluble drugs representing acidic (indomethacin), basic
(carvedilol), and neutral (fenoﬁbrate) categories have been studied. The macroscopic solubility behavior agrees with literature
and exhibits an overall increasing solubility from low pH and total amphiphile concentration to high pH and total amphiphile
concentration. Within the matrix, all three drugs display diﬀerent topographies, which can be related to the statistical eﬀect
levels of the individual amphiphiles or amphiphile interactions on solubility. The study also identiﬁes previously unreported
three and four way factor interactions notably between bile salt, phospholipid, pH, and total amphiphile concentration. In
addition, the results also reveal that solubility variability is linked to the number of amphiphiles and the respective ratios in the
measurement ﬂuid, with the minimum variation present in systems containing all four amphiphiles. The individual 4CMD
experiments within the matrix can be linked to provide a possible intestinal solubility window for each drug that could be
applied in PBPK modeling systems. Overall the approach provides a novel overview of intestinal solubility topography along
with greater detail on the impact of the various factors studied; however, each matrix requires 351 individual solubility
measurements. Further studies will be required to reﬁne the experimental protocol in order the maximize information garnered
while minimizing the number of measurements required.
KEYWORDS: solubility, four component mixture design, pH, total amphiphile concentration, Biopharmaceutics Classiﬁcation System,
FaSSIF, FeSSIF, IVIVC
■ INTRODUCTION
Oral administration of solid dosage forms is simple and
convenient, and therefore, it is the predominant route of drug
administration. Despite the routine process of oral admin-
istration, the drug must be absorbed from the gastrointestinal
tract into the circulation if systemic therapeutic eﬀects are to
occur. The rate and extent of drug absorption is inﬂuenced by
a multitude of factors related to the drug’s physicochemical
properties, the formulation, gastro-intestinal tract physiology,
and the patient, with respect to food intake or clinical status.1
A preeminent factor is the drug’s aqueous solubility, since solid
drug is not absorbed, and therefore dissolution, which is in part
controlled by solubility,2 has to occur after the administration
of a solid dosage form. The importance of aqueous solubility
has been recognized in the Biopharmaceutics Classiﬁcation
System (BCS),3 which categorizes drugs based on either a high
or low solubility with respect to dose. Low aqueous solubility
drugs present a problem during oral administration, since
solubility may impact drug absorption and is an increasing
issue in drug development due to the proliferation of low
solubility compounds.4 However, it has been recognized, that a
simple aqueous assessment does not always reﬂect gastro-
intestinal solubility5 due to the presence of multiple
components (for example bile salts) or physiological
conditions (for example pH) which inﬂuence solubility.
In order to measure gastrointestinal solubility, several
investigators have developed approaches to sample human
intestinal ﬂuid (HIF)6 and to determine the solubility of drugs
in these ﬂuids.7,8 These early forays have been expanded, and
multiple studies have been conducted to determine the
solubility of a range of drugs9,10 in both fasted11 and fed12
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HIF samples. These studies have also demonstrated the
variability of HIF composition between individuals13 and also
between anatomical locations within the intestinal tract.14−16
In solubility studies, however, this variability can be normalized
or reduced, since HIF samples may be pooled or combined to
overcome HIF sample volume limitations.9,10,12,14,17 Solubility
studies in HIF, although the most relevant measurement ﬂuid,
are therefore hampered by the anatomical diﬃculty of
sampling, sample volume, and the inherent variability.
In order to mitigate the issues associated with HIF,
simulated intestinal ﬂuids (SIF) have been developed,
employing physiologically relevant conditions (e.g., pH)10,15
and component concentrations (e.g., bile salt and lecithin).18,19
These initial SIF media recipe studies have been modiﬁed by
multiple groups to improve solubility performance with respect
to HIF (for tables of fasted and fed recipes see refs 20−22); for
example, a recent paper presented ﬁve literature versions of
fasted SIF and proposed a further modiﬁcation based around
altered bile salt and phospholipid concentrations and surface
tension measurements.23 In this study, a solubility comparison
of ten poorly soluble drugs in three diﬀerent media, including
the proposed version, indicated that, for eight drugs, signiﬁcant
solubility diﬀerences between medias were present. Although it
was reported that solubility values in the proposed media were
closer to literature solubility values in HIF samples.
Statistical design of experiment (DoE) investigations into
the solubility contribution of eight typical SIF media
components included in either fasted24 or fed25 recipes
indicated that solubility diﬀerences of up to several orders of
magnitude were possible, even with biorelevant component
concentrations.26 These studies highlighted that media pH is a
major solubility driver for ionizable acidic drugs, and for poorly
soluble basic or nonionizable drugs, four biorelevant
amphiphiles (bile salt, phospholipid, oleate, and monoglycer-
ide) were of equal importance to pH. The studies also
suggested interesting drug speciﬁc solubility variations induced
by media components,24,25 and that other components (buﬀer,
salt, and pancreatin) did not impact solubility unless speciﬁc
interactions were present. However, the DoE approach did not
visualize the subtle interplay of component concentrations and
ratios on solubility and potentially induced variability due to
the statistical design.
Solubility determination in a single intestinal media
composition, either HIF or SIF, only provides a single point
solubility measurement and cannot capture the inherent in
vivo variability of intestinal ﬂuid composition and its impact on
solubility. The solubility of drugs is known to vary by almost
an order of magnitude between diﬀerent simulated media
recipes,23,27 but these only represent measurements around a
center point of possible compositional variation. Some studies
have tackled the inﬂuence of media composition on solubility
by studying the variation of single factors within the system.
The solubility of danazol, for example, has been linearly related
to bile salt concentration8 in sampled HIF, and variation in
cholesterol concentration in a simulated media can either have
no impact, increase, decrease, or induce a minima in the
solubility of carbamazepine, fenoﬁbrate, danazol, and griseo-
fulvin, respectively.28 The application of statistical analysis
methods is also possible,24−26 with one study stating that there
was a “complex interplay” of factors involved.12
The DoE studies mentioned above determined that in
simulated media, pH and the four amphiphilic components
(sodium oleate (SO), phospholipid (soya phosphatidyl choline
(SPC)), bile salt (sodium taurocholate (NATC)), and mono-
oleate (glyceryl mono-oleate (GMO))) were major factors
inﬂuencing solubility. In mixture design experiments, the
mixture components represent independent factors expressed
as fractions of the total sum of the components, which must
add to one, with a ternary phase diagram illustrative of a three
component system. To visualize the complex solubility
interplay between the drug and the amphiphilic components,
a four component mixture design (4CMD), which requires a
tetrahedron, has been applied to seven poorly soluble BCS
class II drugs at a single pH of 7 and total amphiphile
concentration of 11.7 mM.29 However, in this study, only a
single pH (7) was employed to ensure that, within the system,
SO remained ionized and also only a single total amphiphile
concentration (11.7 mM) representitive of the fasted state.
The results provided a visualization of solubility behavior
within the 4CMD space, indicating that all the drugs displayed
diﬀerent solubility patterns with diﬀerent minima and maxima,
including the number of maxima, and the relative proximities
of low and high solubility zones.
It is known, that pH and amphiphile concentrations vary
along the length of the intestinal tract coupled with intra- and
interindividual variations.14−16 In order to determine if the
solubility complexity demonstrated using a single 4CMD
condition25 is retained when pH and amphiphile concentration
varies, we have extended the 4CMD approach to cover
additional pH (5 and 6) and total amphiphile concentration
(30.6 and 77.5 mM) values to provide a 3 × 3 matrix (pH 5, 6,
and 7; total amphiphile concentration 11.7, 30.6, and 77.5
mM) that spans the likely range of biorelevant intestinal values
or conditions. This approach ﬁxes the pH and total amphiphile
concentrations, thus permitting an analysis of the impact of the
amphiphile ratio on equilibrium solubility under multiple
conditions. This has been applied to representative BCS Class
II drugs (Table S1) with an acidic (indomethacin), basic
(carvedilol), and neutral (fenoﬁbrate) example. Our previous
DoE studies24,25 indicate that these categories of drugs are
likely to exhibit diﬀerent behaviors in this system based on the
pH and amphiphiles. This will provide a direct visualization of
the solubility proﬁle across intestinal media component space;
permit comparison of the inﬂuence of total amphiphile
concentration, amphiphile ratio, and pH on solubility top-
ography; along with the statistical signiﬁcance of each
amphiphile and their interactions.
■ MATERIALS AND METHODS
Materials. Hydrochloric acid (HCl), potassium hydroxide
(KOH), acetic acid, sodium dihydrogen orthophosphate
(NaH2PO4), sodium chloride (NaCl), chloroform, indome-
thacin, and fenoﬁbrate were sourced from Sigma-Aldrich, UK.
Carvedilol was kindly provided through the OrBiTo initiative
by Dr. R. Holm, Head of Preformulation, Lundbeck, Denmark.
NATC was purchased from Sigma-Aldrich. Lecithin S PC
(phosphatidylcholine from soybean “98%”, SPC) was
purchased from Lipoid, Germany. SO was obtained from
BDH Chemical Ltd., Poole England. GMO was a gift from
Croda International. All water used was ultrapure Milli-Q
water. Methanol and acetonitrile were HPLC grade (VWR,
UK), and ammonium acetate was obtained from Merck,
Germany.
4CMD. The 4CMD was constructed using Minitab 16.0
simplex lattice with four component input. The lattice
incorporated 4 amphiphiles (NATC, SPC, SO, and GMO),
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and the design was augmented with axial points, which
included points inside the tetrahedron rather than just the
surface. On the basis of the published SIF, DoE experi-
ments,24,25 and HIF compositions,15 pH values of 5, 6, and 7
and total amphiphile concentrations of 11.7, 30.6, and 77.5
mM were chosen to cover a range of possible intestinal values.
This provided a 3 × 3 matrix of 4CMD experiments, each at a
deﬁned pH and total amphiphile concentration.
Each 4CMD experiment within the matrix was identical
(with the exception of pH and total amphiphile concentration)
and contained 39 media compositions, including 5 inside the
tetrahedron (Table 1) and 34 on the four surfaces (Figure 1).
Each tetrahedron face represented a ternary phase diagram
with the absence of one amphiphile, and the four faces are
represented as triangle A, no phospholipid NATC/SO/GMO;
triangle B, no bile salt SPC/SO/GMO; triangle C, no sodium
oleate NATC/SPC/GMO; and triangle D, no monoglyceride
NATC/SPC/SO. Each face had 15 combinations, with the
three points on each edge shared by two faces, and the vertex
points shared by three faces. The concentrations are given in
mol % of the total amphiphile molar concentration, either 11.7,
30.6, or 77.5 mM.
Equilibrium Solubility Measurements. Phosphate buﬀer
containing 68 mM NaCl and 45 mM NaH2PO4 was prepared
with deionized water, and the pH was adjusted to the required
pH. Stock solutions of NATC and SO were freshly prepared
from solids by being dissolved in the phosphate buﬀer. The
SPC stock solution was prepared by dissolving the lipid in
chloroform, removing the chloroform by evaporation under
nitrogen, and dispersing the dried SPC ﬁlm into phosphate
buﬀer. GMO cannot dissolve in buﬀer, so the stock GMO was
prepared by mixing NATC and GMO (1:10.7 ratio) at the
required total concentration, and for practical experimental
reasons, this solution was employed as 100 mol % GMO. The
required 4CMD media was prepared from the stock solutions,
and equilibrium solubility was determined as follows.
An excess amount of solid drug (10 mg) was added to 4 mL
of each mixed lipid media in Corning 15 mL centrifuge tubes
and then placed on a rotating wheel mixer for 1 h. After which,
if required, the pH was readjusted to the desired value in order
to maintain a constant pH during the experimental period.
Tubes were then placed on the mixer and equilibrated at 37 °C
for 24 h, with pH being checked after incubation. This time
frame and procedure has previously been shown to provide a
reproducible determination of equilibrium solubility.24,25,29
The saturated supernatant was separated by centrifugation at
13 000 rpm for 5 min and transferred for HPLC analysis using
an Agilent Technologies 1260 Series Liquid Chromatography
system with Clarity Chromatography software (see Table S2
for analysis details). Each 4CMD experiment was conducted
once.
Statistical Analysis and Graphical Presentation. The
measured equilibrium solubility data for each 4CMD experi-
ment were statistically analyzed in Minitab 16.0 to calculate the
statistical eﬀect values for each amphiphile and amphiphile
interaction. The standardized eﬀect value for each amphiphile
can be calculated by dividing the coeﬃcient (which represents
the change in mean response associated with an increase in
that term, while the other terms are held constant) with
standard error, which is similar to a p-value, and thus indicates
the eﬀects in the model that are statistically signiﬁcant. There
is no p-value generated for each 100 mol % amphiphile (single
parameter terms), but only standardized eﬀect values show the
magnitude of eﬀect. The standardized eﬀect values of each
single amphiphile are closely related with the solubility in the
media that has 100 mol % of that amphiphile; thus; the higher
the value, the higher the solubility within the pure amphiphile.
Note, that pH or total amphiphile concentration are not
variables within an individual 4CMD experiment and therefore
cannot be reported, other than by comparison across the
matrix. The Kolmogorov normality test was used in Minitab to
assess the distribution of each 4CMD data set; on the basis of
the result that some data sets have a non-normal distribution,
the Mann−Whitney test was universally applied to evaluate
diﬀerences between 4CMD data sets and the comparator
fasted and fed DoE data sets.
Surface ternary contour plots with smoothing (Figure 3)
were generated in Matlab R2015a on Mac OSX 10.10.5 using a
contour plot from Alchemyst-ternplot-9c72b90. The solubility
topography plot (Figure 7) was generated in Matlab R2015a
on Mac OSX 10.10.5 using the surface mesh plot function and
the center point values from each 4CMD experiment within
the matrix. The remaining ﬁgures were generated using either
Prism 7.0d or DataGraph 4.3 on Mac OSX 10.10.5.
■ RESULTS
Measured Equilibrium Solubility Distributions. In
Figure 2, the measured equilibrium solubility distributions
for each 4CMD experiment (surface and internal points)
Table 1. 4CMD Composition of Internal Points
component mol %
media composition
bile
salt monoglyceride phospholipid
sodium
oleate
high bile salt 62.5 12.5 12.5 12.5
high
monoglyceride
12.5 62.5 12.5 12.5
high phospholipid 12.5 12.5 62.5 12.5
high sodium oleate 12.5 12.5 12.5 62.5
center point 25 25 25 25
Figure 1. 4CMD representation of surface points. Flattened
representation of the four surfaces of the tetrahedron when open
from the top vertex, which is 100 mol % bile salt, and the remaining
100 mol % vertices are labeled with the appropriate amphiphile.
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within the matrix are presented as box and whisker plots
grouped by pH and total amphiphile concentration along with
reported literature solubility values in both sampled and
simulated intestinal ﬂuids17,30 and distributions from previous
design of experiment studies.24,25 For all drugs, the single point
literature solubility values from either fasted or fed, simulated
or sampled, intestinal ﬂuids, determined by various protocols
which are not equivalent to the current study, lie within the
envelope of the lowest and highest 4CMD matrix results. The
majority of 4CMD distributions lie within the solubility zone
provided by the lowest fasted and highest fed DoE whisker
values. There are some exceptions to this with carvedilol, the
most obvious producing box distributions that extend above
and below the solubility zone, especially at the higher total
amphiphile concentrations. For indomethacin (two of nine)
and fenoﬁbrate (one of nine), whiskers extend outside the
solubility zone to provide lower values than those reported.
Statistical examination of the solubility distributions
indicates that some systems are not normally distributed
(Nn in Figure 2). Especially for carvedilol, where ﬁve out of
the nine experiments provided non-normal distributions, with
only two for indomethacin and zero for fenoﬁbrate. In general,
the internal points, which contain all four amphiphiles, are
grouped around the 75−25% distribution box, rather than at
the whiskers, although there are exceptions. For indomethacin,
one internal point lies on a lower whisker at low pH and total
amphiphile concentration, which is similar for fenoﬁbrate,
where two sit on the low whisker at low pH and total
amphiphile concentration of 30.6 mM. For carvedilol, two
points form whiskers at the total amphiphile concentration of
30.6 mM and pH 5 and 7, respectively.
Indomethacin demonstrates increasing solubility with
increasing pH within each total amphiphile concentration,
with an increased variability, especially to lower values, also
related to the total amphiphile concentration. Statistically
equivalent indomethacin experiments tend to be grouped
based on pH, the low pH, low total amphiphile experiments
are equivalent to the fasted DoE with the high pH, high total
amphiphile concentration experiments equivalent to the fed
DoE. For carvedilol, there is an apparent small increase in
solubility with total amphiphile concentration, and within the
lowest total amphiphile concentration (11.7 mM), there is a
decrease in solubility with increasing pH. However, it is
interesting that the systems at a total amphiphile concentration
of 30.6 mM are statistically equivalent to each other and to the
experiments at lower or higher total amphiphile concentration.
Also the experiments at a total amphiphile concentration of
11.7 mM are equivalent to the fed DoE, with the pH 7 system
also equivalent to the fasted DoE, with the only other
equivalence being the pH 6 total amphiphile concentration of
30.6 mM to the fed DoE. There is also a marked increase in
solubility variability at pH 5 and 6 at total amphiphile
concentrations of 30.6 and 77.5 mM that is reduced at the
highest pH tested. Finally, fenoﬁbrate shows a trend of
increasing solubility with increasing total amphiphile concen-
tration but no pH eﬀect, since experiments within a total
amphiphile concentration grouping are generally equivalent.
This is also reﬂected in the comparison between individual
4CMD experiments and the previous fasted and fed DoE
distributions where, for the latter, generally fasted is equivalent
to the low concentration total amphiphile experiments and pH,
with the fed being equivalent to the higher concentration total
amphiphile experiments and pH.
Figure 2. A statistical comparison of measured equilibrium solubility
distributions. Measured equilibrium solubility distributions presented
as box and whisker plots based on measurement pH and total
amphiphile concentration. Each box and whisker represents all the
data measurements from one 4CMD experiment from high to low,
maximum value, 75th percentile; median, 25th percentile; and
minimum value. Total amphiphile concentration as stated on the x-
axis. pH 5, □; pH 6, gray □; and pH 7, ■. Nn, Data distribution of
4CMD is not normal as assessed by the Kolmogorov normality test
Minitab version 16.0. Bars link data sets considered statistically
equivalent (p > 0.05), Mann−Whitney test, Minitab version 16. ○,
4CMD internal points which contain all four amphiphiles, see Table
1. Comparative data: FaSSIF, fasted simulated intestinal ﬂuid; FaHIF,
fasted human intestinal ﬂuid; FeSSIF, fed simulated intestinal ﬂuid;
FeHIF, fed human intestinal ﬂuid. All data were taken with permission
from from refs 30 (Copyright 2010 American Chemical Society) and
17 (Copyright 2014 Elsevier). Fasted DoE data were taken with
permission from ref 24 (Copyright 2015 Elsevier). Fed DoE data were
taken with permission from ref 25 (Copyright 2017 Elsevier). (a)
Indomethacin, (b) carvedilol, and (c) fenoﬁbrate.
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Calculated Surface Equilibrium Solubility Contour
Plots. Figure 3 presents the calculated surface equilibrium
solubility contour plots as a pH and total amphiphile
concentration matrix. The color shades indicate solubility
values, with yellow representing the highest solubility and
black/dark blue the lowest. Note, solubility ranges vary
between ﬁgures, while the color scheme is constant.
It is evident that each drug has a unique proﬁle, either at any
individual 4CMD experiment or across the whole matrix, no
drugs have identical high solubility zones, and also, the extent
and variability of solubility is diﬀerent for each drug. Triangle B
does seem to have a greater involvement in low solubility zones
when compared to the remainder of the tetrahedron. Overall,
variation in solubility is greater than the previous study,29 but
this is to be expected with an increased pH and total
amphiphile concentration range. Generally, solubility for all
three drugs is lowest at the lower left 4CMD experiment at pH
5 and total amphiphile concentration of 11.7 mM and
increases to the top right. However, the magnitude of this
increase varies between the drugs. Carvedilol (Figure 3b)
behaves diﬀerently since the highest solubility is at pH 6 and
77.5 mM.
For indomethacin (Figure 3a) at pH 5 and a total
amphiphile concentration of 11.7 mM, there is a high solubility
zone situated at the junction of triangles A and B and a low
solubility zone around the junction of triangles B and C. These
zones remain in approximately the same position as the total
amphiphile concentration increases with a slight movement of
the high solubility zone to the junction of triangles A, B, and D.
A similar change is seen with the systems at pH 6 and 7 as the
total amphiphile concentration is increased, although the zones
of high and low solubility are in diﬀerent locations. At 11.7
mM, the topography changes as pH increases, and the low
solubility zone in triangles B and C disappears or shifts to the
junction of triangles A, B and D, with a pH induced increase in
overall solubility. For carvedilol (Figure 3b) at pH 5 and a total
amphiphile concentration of 11.7 mM, the high solubility zone
situated within triangle A and also across triangle D shifts
position slightly with a constant pH, but increasing the total
amphiphile concentration to 77.5 mM causes three high
solubility zones in triangles A, C, and D. At pH 6 with an
increasing total amphiphile concentration, there are similarities
in behavior with the initial high solubility point situated
between triangle B and D with a shift as the total amphiphile
concentration increases to high solubility zones at the vertex of
triangles A, C, and D and the low solubility zone in triangle B.
At pH 7, the proﬁle is diﬀerent, with the high solubility zone at
a total amphiphile concentration of 77.5 mM in a similar
location to the zone determined at pH 5 and total amphiphile
concentration of 30.6 mM and no low solubility zone in
triangle B. With constant total amphiphile concentration but
variable pH, the proﬁles are diﬀerent; for example, triangle A
exhibits consistent behavior across the pH ranges at 11.7 and
30.6 mM but a very diﬀerent behavior at a total amphiphile
concentration of 77.5 mM. At pH 5 and 6 and total amphiphile
concentration of 77.5 mM, the highest solubility is at the
vertices of the main triangle (A, B, C, and D combined) but
shifts away from these vertices at pH 7. For fenoﬁbrate (Figure
3c) at pH 5 and total amphiphile concentration 11.7 mM,
there are high solubility zones situated in triangles A, C, and D.
If pH is constant, these zones remain in the same position with
increasing total amphiphile concentration, although a degree of
variation is induced as the solubility increases, especially at the
vertex of triangle A, B, and C. Similar behavior is evident at pH
6 and 7 as the total amphiphile concentration is increased,
although there are changes in the starting locations of the
zones. If pH is changed at a constant total amphiphile
Figure 3. Calculated equilibrium solubility contour plots presented as
a matrix based on measurement pH and total amphiphile
concentration. The color shades attached to individual ﬁgures
represent the calculated solubility contour concentration (mM)
values for each drug. NB, the solubility ranges vary between ﬁgures.
(a) Indomethacin, (b) carvedilol, and (c) fenoﬁbrate.
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concentration, the results are diﬀerent with some interesting
variations between the amphiphile concentrations. At 11.7
mM, the low solubility zone in triangle B moves to the junction
of triangles B, C, and D, which is low NATC and SO but high
GMO. At a total amphiphile concentration of 30.6 mM, there
is an overall lower solubility associated with pH 6 and a similar
Figure 4. Inﬂuence of amphiphile number on measured equilibrium solubility. Indomethacin equilibrium solubility data points determined during
the 4CMD experiment presented as individual points based on the number of amphiphiles present. (Bar) The mean for each individual data set.
(●) In the four amphiphile columns = center point (see Table 1). See the Supporting Information for carvedilol and fenoﬁbrate ﬁgures.
Figure 5. Internal point results. Indomethacin equilibrium solubility data point plots determined during the 4CMD experiment. Data are presented
as a matrix based on measurement pH and total amphiphile concentration. Each individual plot represents the internal data points (see Table 1)
from the 4CMD experiments grouped either by measurement pH or total amphiphile concentration. NB, The surface data points are not included
in this analysis. ●, Center point; ○, high NATC; △, high SO;◇, high GMO; and □, high SPC. See the Supporting Information for the carvedilol
and fenoﬁbrate ﬁgures.
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(to 11.7 mM) shift of the low solubility zone, although this
looks simply to be due to the overall increase in solubility at
the highest pH. The highest total amphiphile concentration
(77.5 mM) is similar to the high solubility zones remaining in
the same location and a loss of the low solubility zone, which
looks to be simply due to an increased overall solubility as pH
increases.
Impact of Amphiphile Number on Measured Equili-
brium Solubility. Each 4CMD experiment consists of 39
measurement points containing either one, two, three, or four
amphiphiles, and data for indomethacin are presented in
Figure 4 (see Figure S1a,b). The results indicate that, in the
majority of cases, the solubility variability is largest with the
one or two amphiphile systems, reduced in the three
amphiphile system, and smallest when all four amphiphiles
are present. In addition, the center point in the majority of
cases is very close to the mean value for the four amphiphile
systems. As before, there are some exceptions to these general
comments; for example, indomethacin at pH 5 and total
amphiphile concentration of 11.7 mM, where one of the
internal points (high oleate) has the lowest solubility, and
carvedilol at pH 5 and total amphiphile concentration of 30.6
mM, where the four amphiphile system exhibits a large
variability.
Internal Point-Measured Equilibrium Solubility Plots.
Each 4CMD tetrahedron contains ﬁve internal points, which,
based on the previous results (Figure 4), exhibit greater
consistency and are presented separately for indomethacin in
Figure 5 (see Figure S2a,b). For indomethacin, the pH
dependency of solubility is again evident with the reduced
inﬂuence of total amphiphile concentration at higher pH.
However, the extreme solubility points presented in the
whiskers are missing, especially at pH 5 and the 77.5 mM total
amphiphile concentration. The carvedilol proﬁle exhibits a
greater variability of behavior but is similar to generally
increasing solubility with total amphiphile concentration, but
particular systems show unusual behavior; for example, the
high oleate ratio exhibits a marked pH dependency at a total
amphiphile concentration of 30.6 and 77.5 mM. Fenoﬁbrate is
again similar to the total analysis, with generally increasing
solubility with increasing total amphiphile concentration but
with some unusual variation. There is an extremely low
solubility measured at pH 5 and a total amphiphile
concentration of 30.6 mM for the high NATC and GMO
systems.
Statistical Factor Analysis. For indomethacin, the highest
single eﬀect value (Figure 6, see Figure S3a,b,c,d) is for NATC,
followed in roughly equivalent importance by GMO, SPC, and
SO, especially at a low pH and the higher total amphiphile
concentration. As the total amphiphile concentration increases,
the magnitude of the eﬀect values decrease and even becomes
negative for SO at pH 5 and a total amphiphile concentration
of 77.5 mM. The carvedilol single eﬀect values are more varied
but also show a decreasing signiﬁcance as the total amphiphile
concentration increases but with no apparent pH inﬂuence.
For fenoﬁbrate, NATC shows a negative impact on solubility
in seven out of the nine systems, with SO generally being the
largest positive factor, except at pH 7 and the 77.5 mM total
amphiphile concentration, where the remaining amphiphiles
exert a strong positive eﬀect.
For indomethacin, 14 signiﬁcant factor interactions (Figure
6b) are present out of a possible total of 54, with ﬁve out of a
possible 18 at a total amphiphile concentration of 11.7 mM,
decreasing to three at the 77.5 mM total amphiphile
concentration. The majority of the interactions are positive,
but two negative interactions are present between NATC and
SO and SPC and SO at pH 7 and the lowest total amphiphile
concentration of 11.7 mM. For carvedilol, the number of
signiﬁcant interactions is similar at 12, but the incidence is
diﬀerent with six out of eight present at the 77.5 mM total
amphiphile concentration and no negative solubility inter-
actions. No consistent pattern is evident in the signiﬁcant
interactions, other than they seem to be greater at the lower
pH values of the highest total amphiphile concentration. At the
highest total amphiphile concentration of 77.5 mM, the
interaction between bile salt and monoglyceride and bile salt
and phospholipid are the largest signiﬁcant interactions at pH
5, reduced at pH 6, and not signiﬁcant at pH 7; this indicates
the detection of a three way interaction between pH with
NATC and either SPC and GMO. Fenoﬁbrate has the highest
number of signiﬁcant interactions at 23, with a consistent
Figure 6. Indomethacin standardized eﬀect values for individual
amphiphiles and two amphiphile interactions. Indomethacin stand-
ardized eﬀect value for individual amphiphiles and amphiphile
combinations calculated by dividing coeﬃcient with standard error;
the dashed line indicates the p-value (p > 0.05). Due to model
limitations, no p-value was generated for single amphiphile terms, only
a standardized eﬀect value. The bars >0 indicate a positive solubility
eﬀect, and the bars <0 indicate a negative solubility eﬀect. NaTC, bile
salt; GMO, monoglyceride; SPC, phospholipid; and SO, sodium
oleate. (a) Indomethacin single standardized eﬀect values; (b)
indomethacin two amphiphile interaction standardized eﬀect values.
See the Supporting Information for the carvedilol and fenoﬁbrate
ﬁgures.
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response since NATC and SPC positively interact in eight out
of the nine experiments. In addition, there is a pattern that the
interactions have a greater magnitude as the total amphiphile
concentration increases, but at the highest concentration, this
is reduced by the highest pH. This indicates that, for NATC
with GMO or SPC and GMO with SPC, there is a detection of
a possible three way interaction with a pH at the highest total
amphiphile concentration.
Topography of Simulated Intestinal Equilibrium
Solubility. The center points in each 4CMD experiment
represent an equilibrium solubility determination at a
particular pH and total amphiphile concentration and therefore
can be plotted along with a calculated solubility gradient
between the points to provide a visualization of the solubility
topography (Figure 7). Indomethacin exhibits an increased
solubility with increased pH but with an interesting trough at
pH 6 and a total amphiphile concentration of 30.6 mM, and it
also has a reduced solubility at high pH due to high total
amphiphile concentration reducing solubility. Carvedilol has a
diﬀerent topography with increasing solubility, due to
increasing the total amphiphile concentration, and very little
pH eﬀect, except at pH 7 and the highest total amphiphile
concentration. The shape of the topography indicates that this
is a diﬀerent eﬀect to that seen with indomethacin. Fenoﬁbrate
also displays a diﬀerent topography with generally increasing
solubility with increasing total amphiphile concentration but
with a pH induced valley at pH 6 and total amphiphile
concentration of 30.6 mM and a peak at pH 6 and 77.5 mM
total amphiphile concentration.
Intestinal Equilibrium Solubility Window. The previous
results are presented in rank order based on the two main
study variables; however, within the gastrointestinal tract, this
order is irrelevant, and it is known that pH and amphiphile
concentration vary as the material passes down the tract;12,15,16
for example, bile salt is reabsorbed as it moves through the
small intestine. To gauge the possible impact of these media
changes on solubility, Figure 8 presents the span between the
minimum and maximum solubility values of the high ratio
internal points and the center point at a selection of 4CMD
conditions. The starting point is low pH and total amphiphile
concentration (see Figure 8a) reﬂective of proximal small
intestine post gastric transit, followed by rising pH and total
amphiphile concentration, as the material transits and bile is
excreted, and then a reduction in total amphiphile concen-
tration without a major change in pH to mimic the distal small
intestine post absorption. The authors recognize that this
construct is artiﬁcial, but it is similar to research on early,
middle, and late SIFs20 and therefore has a precedent.
The drugs produce three diﬀerent proﬁles, and indometha-
cin (Figure 8b) has an initial low solubility which increases as
the pH increases and is not reduced by the lower total
amphiphile concentrations in the latter analysis stages. The
initial stages provide a solubility window that is lower than the
required high solubility value for BCS Class I, but once the pH
is above 6, all conditions meet the high solubility limit. For
carvedilol (Figure 8c), a more constant solubility proﬁle, with
an approximate center around 1 mM throughout the entire
space, is evident. The result indicates that, based on a 25 mg
dose, carvedilol solubility is counterintuitively in the high
solubility range throughout the analysis space. Fenoﬁbrate
(Figure 8d) has a diﬀerent proﬁle with an initial low solubility
which rises to a maxima at the highest pH and total amphiphile
concentration and then decreases as total amphiphile
concentration decreases. On the basis of a dose of 200 mg,
fenoﬁbrate never achieves a BCS high solubility categorization.
Also of note for all drugs, is that the center point solubility
value is not an average of the low and high solubility window,
Figure 7. The topography of intestinal solubility. Equilibrium
solubility plotted as a 3D topography using the internal center
point solubility result for each drug across the 4CMD matrix. The
color shades attached to individual ﬁgures for the vertical z-axis
represent the solubility contour concentration (mM) values for each
drug; note, that the solubility ranges vary between ﬁgures. (a)
Indomethacin, (b) carvedilol, and (c) fenoﬁbrate.
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its relative position moves through the various experiments,
and each drug displays a diﬀerent behavior.
■ DISCUSSION
General. Each matrix contains 351 solubility measure-
ments, and this is the ﬁrst comprehensive structured
examination of the equilibrium solubility of poorly soluble
orally administered drugs covering pH, four amphiphiles, total
amphiphile concentration, and amphiphile ratio. The use of a
4CMD matrix is novel and restricts comparison with available
literature, where analysis of only single variables in the
presence of multiple constant parameters or nonstatistically
guided approaches or simply diﬀerent measurement protocols
have been applied. This approach allows for analysis of
solubility topography and statistical signiﬁcance of individual
amphiphiles and amphiphile interactions within each 4CMD
experiment but with a ﬁxed pH and total amphiphile
concentration. These latter two variables are known to be
critical parameters inﬂuencing solubility,12,24−26 and in order
to examine their impact, comparison across the matrix is
required which limits statistical analysis since only three data
points are available. In addition, the 4CMD protocol requires
analysis of media that are not biorelevant, for example, 100 mol
% of each amphiphile and amphiphile combinations with
extreme and therefore unlikely biological ratios. This will
produce solubility measurements that are likely to be unusual,
see the Impact of Amphiphile Number on Measured
Equilibrium Solubility section and Figure 4. The discussion
will therefore only examine gross trends within the presented
data and attempt to relate those to prior literature involving the
drugs under study or systems where similar variations of media
components have been examined. In addition, the parameter
values chosen for this study15,31 attempt to cover both the
fasted13,24 and fed12,25 states, and therefore, comparison
requires to examine solubility data obtained under both
conditions.
Overall Solubility Analysis. For all drugs, the published
individual solubility measurements in SIFS or HIFs lie within
the range created by the lowest (25th percentile) and highest
(75th percentile) solubility box line of any of the nine
individual 4CMD experiments. The literature values have been
determined using a range of experimental protocols and media
compositions, and even with this limitation, the comparability
between solubility values demonstrates that the 4CMD values
are in an appropriate range. In addition, the majority of the
4CMD box ranges lie within the lowest and highest solubility
whiskers from the fasted and fed DoE results. There is one
exception, the single measurement of carvedilol solubility in
fasted HIF, which is lower than the 4CMD lowest box
solubility and also lower than the whisker for the fasted DoE
solubility range. Also, for carvedilol at the highest total
amphiphile concentration, the highest 4CMD box solubility
values exceed the highest solubility whiskers from the fasted
and fed DoE results. Finally, for all drugs, some of the low
solubility 4CMD whiskers extend below the lowest solubility
whisker from the fasted DoE result. Overall these results
indicate that the 4CMD matrix is exploring a relevant solubility
space encompassing and comparable to published data, with
indomethacin and fenoﬁbrate exhibiting excellent compliance,
but carvedilol displaying compliance coupled to aberrant
behavior at the edges of the investigational space. This is
possibly related to the features discussed above (the General
section) and the measurement within the matrix of the extreme
systems (the Calculated Surface Equilibrium Solubility
Contour Plots section) that might be considered to have
limited or no biorelevance.
In general, there is an increase in solubility from the lower
left corner of the matrix (pH 5 and total amphiphile
concentration of 11.7 mM) to the upper right (pH 7 and
total amphiphile concentration of 77.5 mM) (Figures 2, 3, and
4). This can be compared to the solubility increase that occurs
on shifting from fasted to fed in either sampled or simulated
media11,17,31,32 and agrees with the published DoE results,
which indicate that increased pH and amphiphile concen-
tration drive solubility.24,26,31 In addition, a study using the
same four amphiphiles with estradiol indicated that solubility
Figure 8. Intestinal equilibrium solubility window using the
maximum, minimum, and center internal point solubility results
from selected 4CMD experiments (see (a) and Figure 5). TAC, total
amphiphile concentration. The dashed line indicates the required
solubility for the stated dose dissolved in 250 mL to be classed as the
high solubility with the BCS. (b) Indomethacin, dose = 50 mg; (c)
carvedilol, dose = 25 mg; and (d) fenoﬁbrate, dose = 200 mg.
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was increased as total amphiphile concentration increased,
although this only examined three systems at a constant ratio
and pH.33 Other studies which examined mixed systems22,34
have reported the same relationship between drug solubility
and total amphiphile concentration, with one reporting22
interesting variations between drugs. This variation in
solubility behavior related to total amphiphile concentration
is also evident in these results; for example, some carvedilol
systems in Figure 5b exhibit a maxima at a total amphiphile
concentration of 30.6 mM. These comparisons indicate that
the 4CMD matrix is examining a relevant solubility space, and
that the systems macroscopic solubility behavior is comparable
to literature studies.
The measurement points contain a range of amphiphile
ratios and numbers (Figure 1 and Table 1), which allows for a
solubility comparison between systems with the same pH and
total amphiphile concentration but varying amphiphile
numbers and ratios (Figure 4). There are no comparable
literature studies with this type and arrangement of data. The
striking general result of this analysis across all three drugs is
that systems with one or two amphiphiles exhibit a large degree
of solubility variability, which is lower in systems with three
amphiphiles and minimum in the systems containing all four
amphiphiles. In the majority of the 4CMD experiments, the
center point, which contains all four amphiphiles in an equal
ratio, is very close to the mean for the four amphiphile points.
In addition, Figure 3 indicates that the four amphiphile points
are generally within the distribution box plots. There are
exceptions for three of the points (out of a possible 108), with
two for fenoﬁbrate at pH 5 and a total amphiphile
concentration of 30.6 mM and indomethacin at pH 5 and a
total amphiphile concentration of 11.7 mM. The behavior of
indomethacin is diﬀerent, with a lower solubility variability at
higher pH values, which can be explained by the ionization of
the drug dominating solubility behavior. The data indicate that
equilibrium solubility at a constant pH and total amphiphile
concentration is heavily inﬂuenced by the number of
amphiphiles present and the ratio of the amphiphiles, and
reducing the spread of ratios and increasing the total number
of amphiphiles reduces the solubility variability. Further
research in systems structured to examine this eﬀect will be
required to fully determine the impact of this ﬁnding.
For each 4CMD experiment, the data were analyzed for a
normal distribution pattern. For indomethacin and carvedilol,
two or ﬁve, respectively, of the nine 4CMDs do not exhibit
normality; whereas, for fenoﬁbrate, all the systems are normally
distributed. Deviations from normality have been reported in
DoE solubility studies,31,35 where it may arise either through
the sample pattern induced by the DoE structure and/or the
fact that drug solubility is not normally distributed in the
sample space. The 4CMD protocol samples uniformly across
the space within a tetrahedron (Figure 1) and therefore should
report a normal solubility distribution, if present, unlike the
DoE, which statistically links low and high values of variables
(pH and individual amphiphile concentrations). The rationale
that “drug solubility is not normally distributed” is supported
by HIF characterization studies, which indicate that bile salt
and lecithin in the fasted state have skewed concentration
distributions,13 and HIF solubility studies measuring diﬀer-
ences between mean and median solubility values17,36 indicate
a non-normal solubility distribution. The results of this study,
when coupled with DoE results, indicate that both reasons are
in operation; in DoE, the majority of distributions are non-
normal,31,35 while in this case, deviations are limited to
carvedilol and two for indomethacin. The DoE studies may
therefore overestimate deviations from normality due to the
statistical sampling structure, but these deviations are
inherently present in some systems evidenced by the behavior
of carvedilol in the current 4CMD, the shape of the proﬁles in
Figure 3, and the result in Figure 4, indicating that studies with
two amphiphiles and variable ratios will induce solubility
variability. Absolute resolution of this issue would require the
conduct of studies that randomly sample a particular media
space.
Indomethacin. Indomethacin is a weak acid with a pKa of
4.5, which means that at the lowest pH (5), it will be
approximately 30% nonionized and almost fully ionized at the
highest pH (7); solubility is therefore expected to increase due
to drug ionization. With increasing pH, increasing solubility is
evident along with the impact of the amphiphiles, where
solubility variability decreases with increasing pH at a constant
total amphiphile concentration but increases with increasing
total amphiphile concentration at the same pH. The solubility
of the 4CMD systems at pH 7 as well as pH 6 at 77.5 mM are
statistically equivalent, indicating that pH is the major
solubility driver but also that amphiphiles inﬂuence solubility.
This pattern is consistent with indomethacin DoE results,
where, in the fasted system,24 the ratio of the oleate
standardized eﬀect value to pH was 9, but in the fed,25 it
was 4, indicating the increased inﬂuence of amphiphiles with
respect to pH at higher amphiphile concentrations. New in this
data is that increasing the total amphiphile concentration at
any pH increases the solubility variability by lowering the low
solubility whisker, indicating that particular amphiphiles, ratios,
and or combinations reduce indomethacin solubility, for
example, the high oleate ratio internal point in Figure 5 at
pH 5.
In Figure 3a, the calculated solubility topographies indicate
that if the pH and amphiphile ratio remains constant, but the
total amphiphile concentration is increased, then overall
solubility will increase, and the solubility contour proﬁle will
not change dramatically. This property is already evident in the
literature in several systems that have related solubility to total
amphiphile concentration33,34 or concentrations of individual
amphiphiles8,17 and to studies using combinations of synthetic
surfactants and simulated media.37
If the total amphiphile concentration is constant and the pH
changes, an interesting pattern emerges. As the pH increases,
indomethacin ionization will increase but so too will the
ionization of the amphiphile oleic acid, which has a pKa value
around 5, while the ionization of bile salt with a pKa of 2 will
not change substantially.38 The impact of ionization is evident
in Figure 3a, since the vertices, which represent 100 mol % bile
salt, are high solubility zones at pH 7 but not at pH 5,
indicating that as indomethacin ionization increases, the
interaction with bile salt increases (see also Figure 6a). This
interaction may be electrostatic in nature, and it has been
reported, that indomethacin permeation in vitro is reduced by
bile salts,39 providing further evidence for this interaction. In
Figure 5a, the increased solubilization by ionization of oleate is
evident in the high oleate point at total amphiphile
concentrations of 11.7 and 77.5 mM. Both amphiphiles have
positive standardized eﬀect values as single agents (Figure 6a),
a result that was also present in the fasted24 and fed25 DoE,
where, in addition, a signiﬁcant positive interaction was
reported between the amphiphiles and pH except for bile
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salt and pH in the fed system. In the present study, both
amphiphiles do exhibit signiﬁcant positive and one negative
interactions (Figure 6d), but in the fasted or fed DoE, no
signiﬁcant interactions between these amphiphiles were
determined. The results in Figure 6d also indicate that there
is a signiﬁcant positive interaction between phospholipid and
bile salt or SO, but in the fasted or fed DoE, no signiﬁcant
interactions between these amphiphiles were determined,
although a multiple linear regression on indomethacin in
intestinal ﬂuids linked bile salt and the phospholipid.12 This
analysis indicates that if pH changes, solubility will increase,
but the topography will also change due to changes in
amphiphile ionization. In addition, it indicates that the DoE
approach may miss subtle interactions between components if
swamped by a dominant factor, for example, pH, which in this
study is a constant within each 4CMD experiment. Overall the
behavior agrees with a previous study on the solubility of
indomethacin in HIF that attributed 90% of the solubility to
pH and 10% to bile salt and phospholipid.12
This results in a solubility topography with the major slope
rising from low to high pH, with a lower gradient slope based
on total amphiphile concentration (Figure 7a). There are two
interesting gross features in the topography, a maximum
solubility ridge, that runs between pH 7 and a total amphiphile
concentration of 30.6 mM and pH 6 77.5 mM, and a solubility
valley at pH 6 and 30.6 mM. The maximum solubility ridge
forms due to the lower solubility at pH 7 and total amphiphile
concentration of 77.5 mM, indicating that high amphiphile
concentrations reduce indomethacin solubility, even although
it is fully ionized. On the basis of the results in Figure 8b, this is
not likely to impact indomethacin absorption, but this result is
not present in the literature, and if this is a general property of
acidic drugs, it would be important. The low solubility trough
at pH 6 and 30.6 mM total amphiphile concentration is
interesting and evident in the results presented in Figures 3a,
5a, and 7a, where this system behaves in an inconsistent
manner when compared to the other total amphiphile
concentrations at this pH. Figure 5a indicates that this is a
systematic eﬀect since all four amphiphile ratios exhibit the
response, and this type of behavior (a solubility minima)
related to the amphiphile concentration has been reported
previously in the literature with cholesterol containing media
and griseofulvin.28
Carvedilol. Carvedilol is a weak base with a reported pKa
between 7.8 and 8.25;40 therefore, throughout the 4CMD pH
range, it will be ionized, with a minimum percentage ionized of
90% at pH 7, if the pKa is taken to be 8. It is also reported to
have a low and variable solubility in a range of buﬀers41 and
intestinal media systems.17 In this study, it displays a diﬀerent
proﬁle to indomethacin (Figure 3b) ,where neither pH or total
amphiphile concentration markedly inﬂuence overall solubility.
There is evidence of a pH eﬀect at the low total amphiphile
concentration, where solubility decreases as pH increases, but
this is only statistically signiﬁcant between pH 5 and 6. Eight of
the data sets are statistically equivalent, which covers
comparisons within and between 4CMD experiments as
grouped by total amphiphile concentration (Figure 2b). In
addition, ﬁve of the nine 4CMD experiments provide data sets
that are not normally distributed, compared to only two for
indomethacin and zero for fenoﬁbrate. The solubility range of
each 4CMD is also variable, and no pattern is evident, except
maybe that pH 7 has a reduced variability at total amphiphile
concentrations of 30.6 and 77.5 mM, and that the lowest total
amphiphile concentration has the lowest overall variability
irrespective of pH. The calculated solubility peaks and troughs
(Figure 3) shift as both pH and total amphiphile concentration
change, indicating a complex solubility behavior inﬂuenced by
pH, total amphiphile concentration, and ionization of the
amphiphiles.
The statistical signiﬁcance of the individual amphiphiles (see
the Supporting Information) indicates that they all exert a
roughly equivalent positive solubility impact, with phospholi-
pid possibly being the most signiﬁcant. In the published fasted
DoE, oleate and lecithin provided a small but statistically
signiﬁcant positive solubility inﬂuence, while bile salt had a
small but signiﬁcant negative eﬀect.24 In the fed DoE, oleate
and bile salt had a signiﬁcant positive solubility inﬂuence, while
phospholipid was only just signiﬁcant.25 An alternative DoE
study indicated that bile salt had a negative impact on
solubility, phospholipid was not signiﬁcant, and oleate was not
studied.26 These studies together indicate that, for carvedilol,
the amphiphiles inﬂuence solubility, but that no single
amphiphile predominates over the whole 4CMD matrix.
There are only 12 signiﬁcant amphiphile combinations
interactions out of a possible 54 but with an indication of a
pH dependency at the highest total amphiphile concentration.
The statistical signiﬁcance matches the solubility behavior,
especially at the total amphiphile concentration of 77.5 mM,
where, at pH 7, SPC and SO are signiﬁcant, while at lower pH
values, NATC with GMO or SPC is signiﬁcant. In the fasted
state DoE, the combination of oleate and bile salt had a
signiﬁcant negative solubility inﬂuence, while in the fed state,
the combination of phospholipid and either oleate or
monoglyceride had a signiﬁcant positive impact. Another
study indicated the pH and bile salt had a positive inﬂuence on
solubility but did not determine any interaction between the
amphiphiles.26 This is evident where the signiﬁcance of the
interactions is higher at the highest total amphiphile
concentration, and in addition, the inﬂuence of pH on these
interactions can be seen. There is literature evidence that the
solubility of carvedilol in mixed simulated media and surfactant
systems is dependent upon the surfactant,37 and in one study
of surfactants, NATC42 displayed a poorer solubilization than
cationic or nonionic surfactants. This behavior is evident in the
4CMD carvedilol results in Figure 3b at pH 7 and total
amphiphile concentration of 11.7 mM, where the low solubility
zone is at the three vertices of the tetrahedron, which is 100
mol % bile salt, but this is reversed at pH 5 and total
amphiphile concentration of 77.5 mM, where the high
solubility zone is now in these vertices.
The two factor interactions between NATC and either
GMO or SPC at a total amphiphile concentration of 77.5 mM
have the greatest magnitude at pH 5, a lower magnitude at pH
6, and are not signiﬁcant at pH 7. This indicates identiﬁcation
of two, three-way parameter interactions, NATC with pH and
either GMO or SPC; the fact that this is only visible at 77.5
mM might also indicate that total amphiphile concentration is
a fourth factor in this interaction. There is weaker evidence for
a similar behavior of SPC with SO when combined with pH
and total amphiphile concentration. The previous DoE studies
were not powered to detect three- or four-way parameter
interactions, and this is, we believe, the ﬁrst report of a three-
or possibly four-way solubilization interaction in SIFs.
For carvedilol at a constant pH, increasing the total
amphiphile concentration induces changes in solubility top-
ography, and if total amphiphile concentration is constant and
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pH is changed, this induces diﬀerent changes in the solubility
topography. Overall, this indicates that, for carvedilol at either
a constant pH or total amphiphile concentration, the solubility
topography changes as other variables change and results in a
complex pattern that is diﬃcult to interpret but pH, total
amphiphile concentration, and amphiphile ratio dependent.
The solubility changes are within a relatively small range, with
only a 25-fold variation based on the lowest 25th percentile
(approximately 0.2 mM) to the highest 75th percentile
(approximately 5 mM) (Figure 3b), compared to 100 for
fenoﬁbrate (Figure 3c). This results in a solubility topography
(Figure 7b) that is very ﬂat at all pH values and low total
amphiphile concentrations but then increases markedly at the
highest total amphiphile concentration, with a maximum
solubility at pH 6 and 30.6 mM total amphiphile
concentration.
Overall, the results indicate that, in this system, carvedilol is
displaying a complex solubility behavior (ﬁve out of the nine
4CMD experiments produce non-normal solubility distribu-
tions) that is inﬂuenced by multiple interdependent factors,
such as pH, amphiphile ratio, ionization, and total amphiphile
concentration. The identiﬁcation of three- and possibly four-
way parameter interactions within the matrix highlights the
sensitivity of the analysis and also the complexity of carvedilol’s
behavior. This is replicating the variable solubility behavior of
carvedilol reported in the literature,17,41 with no single factor
across the 4CMD matrix dominating an outcome that is similar
to the fasted24 and fed25 DoE results. Carvedilol is a
challenging molecule to examine in these systems!
Fenoﬁbrate. Fenoﬁbrate is a neutral drug and will not
undergo changes in ionization. It displays a diﬀerent proﬁle to
both indomethacin and carvedilol, with solubility increasing as
total amphiphile concentration increases, with minimal
changes due to pH, except at the lowest total amphiphile
concentration. All of the 4CMD experiments produce a normal
distribution but display very low solubility whiskers, and at the
highest total amphiphile concentration, the 75th percentile
solubilities are higher than the same value for the fed DoE. The
low whiskers are probably, as stated previously, a reﬂection of
the 4CMD sampling proﬁle, while the higher values reﬂect the
high total amphiphile concentration employed, when com-
pared to previous literature43 and standard fed-simulated
media recipes. Overall, this indicates that fenoﬁbrate is
behaving in the 4CMD matrix in a manner that is consistent
with published results.
At a constant pH, as the total amphiphile concentration
increases, the solubility zones remain in the same position
(Figure 3c), although a degree of variation is induced as the
solubility increases. This is also evident (see Figure S2b)
where, at constant pH, the internal points remain in the same
general solubility ranking as total amphiphile concentration
increases. A aimilar behavior is evident at pH 6 and 7 as the
total amphiphile concentration is increased, although there are
changes in the starting locations of the high and low solubility
zones. Therefore, for fenoﬁbrate, in a similar manner to
indomethacin, the solubility will increase as the total
amphiphile concentration increases with minimal changes to
topography; the latter feature, as stated above, is already
evident in the literature for similar systems7,17,33,34 and studies
using combinations of synthetic surfactants and simulated
media.37
If pH is changed at a constant total amphiphile
concentration, the results are diﬀerent with some interesting
variations to the solubility zones. This change can also be
visualized in the internal points (see Figure S2b), where the
high SO point has the lowest solubility at pH 5 but is the
highest at pH 7. These results indicate that pH does not have a
major inﬂuence on solubility but does impart topographical
changes as the amphiphile ionization changes, and the
magnitude of this eﬀect is greater at the lower total amphiphile
concentrations. The published fed DoE studies25 and a full
range DoE study31 reported that pH was not a statistically
signiﬁcant parameter for solubilization but was in the fasted
study,24 where it had a negative impact. Indicating that the
4CMD matrix is replicating behavior that is present in the
published literature.
The statistical signiﬁcance of the individual amphiphiles (see
Figure S3c,d), indicates that NATC consistently exerts a
negative eﬀect on solubility, a feature that can be seen in all the
4CMD experiments, where the vertices of the tetrahedron,
which is 100 mol % BS, are low solubility zones. The remaining
amphiphiles generally have a positive solubility impact, with
oleate exhibiting the strongest activity with interesting pH and
total amphiphile concentration variations. This concurs with
the published fasted,24 fed,25 and full range31 DoE results,
where oleate was the amphiphile with the highest standardized
eﬀect value on fenoﬁbrate solubility, and bile salt had a
negative impact in the fed study but positive in the fasted and
full range. However, an alternative DoE containing only bile
salt and phospholipid indicated that both had a signiﬁcant
positive eﬀect on solubility.26 For the factor interactions, 23
out of 54 are signiﬁcant, with some interesting changes as total
amphiphile concentration and pH change. The most consistent
signiﬁcant positive interaction is between bile salt and
phospholipid, which was also the most signiﬁcant factor
interaction reported in the fasted and full range studies but not
signiﬁcant in the fed study. In the current study, this
interaction also exhibits a pH eﬀect at the highest total
amphiphile concentration (77.5 mM) as the magnitude of the
value decreases as pH increases, a result that could be applied
to all the interactions since only one remains signiﬁcant at pH
7. This is evidence of a three-way interaction (pH with bile salt
with phospholipid), and possibly even a total amphiphile
concentration inﬂuence which would provide a four-way
interaction. However, the DoE studies report that the
interaction of bile salt with pH and bile salt with lecithin are
statistically signiﬁcant but not lecithin with pH (except in ref
26), indicating that the level of detail available from any study
is linked to the experimental design. One study12 has
performed a multiple linear regression to determine the factors
which inﬂuence the solubility of neutral compounds (danazol
and nifedipine) in postprandial ﬂuids, indicating that
approximately 70% of the solubility could be ascribed to the
factors studied with a combination of bile salt and
phospholipid, contributing, for both drugs, approximately
50% and for nifedipine fatty acids and monoglycerides between
25 and 30% and pH approximately 15%. The behavior of
fenoﬁbrate in the current 4CMD system is therefore consistent
with the published data and reveals further subtle details on the
relationship between solubility and media factors.
This is reﬂected in the overall solubility topography
presented in Figure 7c, where the greatest slope arises due to
increasing total amphiphile concentration and displays two
features that are similar to the behavior of carvedilol and
indomethacin. The maximum solubility is at pH 6 and a total
amphiphile concentration of 30.6 mM, similar to carvedilol,
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indicating that pH 7 and a total amphiphile concentration of
77.5 mM suppress fenoﬁbrate solubility. There is also a
solubility minima at pH 6 and a total amphiphile concentration
of 30.6 mM, which is similar to indomethacin.
Impact of Media Composition. The experimental
protocol utilizes four amphiphiles, which are known to
inﬂuence the equilibrium solubility of poorly soluble
drugs.24,25 The critical micelle concentration of the amphi-
philes (NATC, 8−12 mM;44 SO, 2.2−4 mM;45 GMO, 0.004
mM;46 and SPC, 0.4 mM47) is below the lowest total
amphiphile concentration (11.7 mM); therefore, the media
within the matrix will be a colloidal system that will consist of a
range of structures (micelles, mixed micelles, and
vesicles),33,48−50 which will change as molar ratio (within a
4CMD changes), concentration, and pH (across the matrix)
vary. This study did not examine colloidal structures, but the
results indicate that changes in these structures are inﬂuencing
solubility (Figure 3). Other research groups have presented
solubility inﬂections related to amphiphile concentration43 or
to the presence of solubility maxima and minima as the ratio of
components changes28,43 behavior that is also evident in this
study.
One interesting feature of the results, visible in Figure 7, is
that the pH 6 and total amphiphile concentration of 30.6 mM
system produces an unusual solubility result for indomethacin
and carvedilol that is lower than the other two pH 6 systems
and results in an negative inﬂection of the lines in Figure 5.
There is not a large solubility variation in this system (Figure
4), implying that this is an inherent property of this set of
conditions. With only three pH values and total amphiphile
concentrations, it is not possible to fully examine the
interesting behavior of the 30.6 mM system. This is worthy
of further study since it may represent a set of conditions with
unusual colloidal properties or where the colloidal structures
inhibit solubility.
Intestinal Equilibrium Solubility Window. The current
study was designed to provide a matrix that would reveal the
solubility behavior of poorly soluble drugs across a range of
simulated media compositions and to investigate the impact of
media components. However, it is also known, that the
composition of intestinal ﬂuids will change as a result of
prandial status, anatomical position within the small intes-
tine,12,14−16 and in relation to inter- and intra-individual
variability.13 In order to apply this information, compartmental
model systems of the gastrointestinal tract have been
proposed,51,52 with some models proposing up to seven
diﬀerent compartments for the small intestine.53 In this study,
each 4CMD experiment represents a set of conditions that
could be related to intestinal compartments or ﬂuid
compositions, as a material was exposed to diﬀerent prandial
states and anatomical locations. A possible scenario (Figure
8a) utilizes ﬁve of the nine experiments, the minimum and
maximum solubility values of the internal points have been
employed since these are more realistic solubility determi-
nations. However, this probably underestimates solubility
variability based on the 25th and 75th percentile range in
Figure 3. This is similar to the use of early, middle, and late
simulated fasted media systems to represent diﬀerent
phases.12,20
The analysis (Figure 8) indicates that the drugs exhibit three
diﬀerent proﬁles. For indomethacin, the impact of pH is
obvious, and once the system is above pH 6, solubility is
suﬃcient to be classed as high within the BCS system. While
for carvedilol, a constant solubility window is evident that is
not inﬂuenced by pH or total amphiphile concentration, and
which is suﬃcient to class the drug as high solubility. For
fenoﬁbrate, a further proﬁle type is evident, with solubility
reaching a maxima linked to the total amphiphile concen-
tration and, even at the maxima, not attaining suﬃcient
solubility to be classed as high. This type of analysis could be
useful for pharmacokinetic predictions and formulation
development, but it must, at this stage, be applied cautiously,
since it does not allow for dynamic changes in composition12,14
or rate of movement down the intestinal tract.54 Of interest is
that the position and proﬁle of the center point relative to the
maximum and minimum internal point values are also diﬀerent
for the three drugs and do not lie directly in the middle of the
solubility window. Indicating that a single point equilibrium
solubility measurement will not allow for possible variability or
indicate its position with respect to the overall solubility range.
■ CONCLUSIONS
This is the ﬁrst 4CMD study of equilibrium solubility using
biorelevant amphiphiles (NATC, SPC, SO, and GMO)
measured within a matrix of three pH values (5, 6, and 7)
and three total amphiphile concentrations (11.7, 30.6, and 77.5
mM) providing a solubility matrix covering the fasted and fed
intestinal media states with visualization of the solubility
topography. The macroscopic solubility behavior within the
matrix is consistent with the published literature in either the
fasted or fed intestinal ﬂuid,17 simulated fasted or fed intestinal
ﬂuid,30 and with statistically based equilibrium solubility
determinations24−26,31 or multiple linear regression.12 The
4CMD matrix is therefore examining a relevant equilibrium
solubility space, although this may not be reﬂected in other
physicochemical properties, such as dissolution.
Overall solubility increases from low pH and total
amphiphile concentration to high pH and total amphiphile
concentrations in a similar manner to switching from fasted to
fed media.35 The behavior of the exemplar acidic (indome-
thacin), basic (carvedilol), and neutral (fenoﬁbrate) drugs is in
agreement with the published DoE24−26 and other statistical
studies.12 For acidic compounds, pH is the major solubility
driver, while for basic and neutral drugs, a combination of pH
and amphiphiles contributes to the solubility. This approach
therefore provides an orthogonal veriﬁcation of the published
literature ﬁndings. In addition, this study identiﬁes, for the ﬁrst
time, three and four factor interactions for two of the drugs
involving pH, NATC, and SPC with total amphiphile
concentration as a fourth factor. Determination of this degree
of interaction has not been previously possible. The results
indicate that all three drugs behave in a diﬀerent fashion at any
point within the matrix and reveal that the complex solubility
topography previously reported using a single 4CMD
condition29 extends throughout intestinal media conditions
irrespective of drug, pH, or amphiphile concentration. The
study conclusively demonstrates that the topography arises due
to the combination of drug, pH, and amphiphile in terms of
number present, total concentration, ratio, and when linked to
pH ionization; all of which will be applicable in both simulated
and sampled intestinal ﬂuids.
The 4CMD statistical design provides a unique view on the
behavior of simulated media systems, indicating that the
greater the number of amphiphiles included within the system,
the lower the measured solubility variability. In addition, the
analysis of solubility distributions for normality (Figure 2)
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indicates that the 4CMD’s uniform sampling structure
determines a lower number of non-normal distributions than
DoE studies.31 These ﬁnding have profound implications for
the design of simulated media systems in terms of the number
of amphiphiles included, the ratios employed, and the
arrangement of sampling points. It appears, therefore, that
further statistical reﬁnement is required to ﬁnd a model suited
to the particular issues and intricacies of intestinal ﬂuid.
The results demonstrate that solubility variability is an
inherent property of these systems, and this reinforces our
previous discussion that “a single point solubility measurement
in a ﬁxed composition media will provide a value that might be
situated in a valley, plateau, slope, or peak”.29 Therefore, in
either simulated media or sampled intestinal ﬂuids, the utility
of a single solubility measurement is limited without a
knowledge of the surrounding solubility topography. In the
research literature, the issue of solubility variability is an ever
present problem that seems to have no resolution, and in this
study, the three drugs investigated produce a diﬀerent
solubility topography implying that every drug will be unique.
However, the “scaleable” topography behavior of indomethacin
and fenoﬁbrate in certain situations indicates that structured
behavior is present, and that guidelines, if not eventually rules,
are possible if a suﬃcient knowledge of the systems can be
obtained. This will not be simple, in this study, carvedilol
displays a behavior that is not easily interpreted, other than too
many factors are inﬂuencing solubility, which swamps the
applied statistical methodology.
In a previous publication,29 it was suggested that the discrete
nature of each individual 4CMD experiment could be tailored
to provide an equilibrium solubility window that could be
applied to PBPK compartmental models of the gastrointestinal
tract. The matrix in the current study was designed to cover
intestinal conditions; however, by judicious choice of 4CMD
experiments from within the matrix, it does permit a possible
visualization of equilibrium solubility in multiple discrete
compartments and indicates the feasibility of this approach.
The result that the three drugs have three diﬀerent proﬁles also
highlights the issues associated with a single point solubility
determination. Future, 4CMD matrices could be speciﬁcally
designed to mimic and study possible gastrointestinal
compartments for PBPK modeling.
The 4CMD matrix approach is resource intensive and not
easily applied during drug development or even typical
research studies, unless high throughput systems can be
developed. The current design can only handle four
components, and it could be argued, that other amphiphiles
should be present, for example, cholesterol13,28 and/or
lysolecithin,23 which would increase the number of measure-
ments required. The results in Figure 4 indicate that the impact
on equilibrium solubility of additional components as “single”
factors in a one or two factor media system would be high;
whereas, in a three or four factor media system, this would not
(unless drug speciﬁc eﬀects are present) be pronounced.
Judicious application of this ﬁnding would reduce the number
of solubility measurements required. Further work will be
required to reﬁne the approach so that the number of samples
can be reduced with the removal of 100 mol % points, two or
three amphiphile mixtures, for example, while a relevant range
of conditions (pH, number of amphiphiles, ratios, and
concentrations) are investigated. However, this is likely to
run into the simple statistical limitation that decreasing the
sample number limits the experiment’s statistical certainty and
resolution.31
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